Literature DB >> 14616787

Increased serum transforming growth factor-beta1 in human colorectal cancer correlates with reduced circulating dendritic cells and increased colonic Langerhans cell infiltration.

A Huang1, J W Gilmour, N Imami, P Amjadi, D C Henderson, T G Allen-Mersh.   

Abstract

Cancer-related cytokines may interfere with the differentiation and migration of dendritic cells (DCs) and with the associated up-regulation of co-stimulatory molecules in vitro. We determined whether cytokines affected the distribution and activation of DCs in patients with colorectal cancer by measuring the levels of serum cytokines [transforming growth factor (TGF)-beta1 and vascular endothelial growth factor (VEGF)], DC numbers and phenotype from peripheral blood and mesenteric lymph nodes draining the cancer, and the infiltration of DCs into colorectal cancer. A significant increase in the serum level of TGF-beta1 correlated with a significant reduction in the level of circulating DCs in cancer patients that was associated with an increased infiltration of Langerhans cells into colorectal mucosa. The prevalence but not intensity of co-stimulatory molecule expression in circulating and mesenteric lymph node DCs was reduced in patients with colorectal cancer compared to patients with inflammatory bowel conditions. There was no correlation between co-stimulatory molecule expression and serum TGF-beta1. Thus the circulating DC depletion in colorectal cancer could be explained by a TGF-beta1-related DC redistribution from the circulation into the colorectal cancer and adjacent mucosa where DC levels were increased. There was an impairment of DC activation within colorectal cancer that was not related to serum level of cytokines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14616787      PMCID: PMC1808854          DOI: 10.1046/j.1365-2249.2003.02295.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  50 in total

1.  Natural adjuvants: endogenous activators of dendritic cells.

Authors:  S Gallucci; M Lolkema; P Matzinger
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

2.  Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules.

Authors:  J Valladeau; O Ravel; C Dezutter-Dambuyant; K Moore; M Kleijmeer; Y Liu; V Duvert-Frances; C Vincent; D Schmitt; J Davoust; C Caux; S Lebecque; S Saeland
Journal:  Immunity       Date:  2000-01       Impact factor: 31.745

3.  Role of tumor cell apoptosis in tumor antigen migration to the draining lymph nodes.

Authors:  B Bonnotte; N Favre; M Moutet; A Fromentin; E Solary; M Martin; F Martin
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

4.  Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease.

Authors:  P Lissoni; L Vigore; R Ferranti; R Bukovec; S Meregalli; M Mandala; S Barni; G Tancini; L Fumagalli; L Giani
Journal:  J Biol Regul Homeost Agents       Date:  1999 Oct-Dec       Impact factor: 1.711

Review 5.  TGF-beta1 regulation of dendritic cells.

Authors:  H Strobl; W Knapp
Journal:  Microbes Infect       Date:  1999-12       Impact factor: 2.700

6.  Respective involvement of TGF-beta and IL-4 in the development of Langerhans cells and non-Langerhans dendritic cells from CD34+ progenitors.

Authors:  C Caux; C Massacrier; B Dubois; J Valladeau; C Dezutter-Dambuyant; I Durand; D Schmitt; S Saeland
Journal:  J Leukoc Biol       Date:  1999-11       Impact factor: 4.962

7.  Transforming growth factor-beta1 polarizes murine hematopoietic progenitor cells to generate Langerhans cell-like dendritic cells through a monocyte/macrophage differentiation pathway.

Authors:  Y Zhang; Y Y Zhang; M Ogata; P Chen; A Harada; S Hashimoto; K Matsushima
Journal:  Blood       Date:  1999-02-15       Impact factor: 22.113

8.  Circulating immature and mature dendritic cells in relation to lymphocyte subsets in patients with gastrointestinal tract cancer.

Authors:  P Lissoni; F Brivio; R Ferrante; L Vigore; M Vaghi; E Fumagalli; R Bucovec; F Malugani; L Fumagalli
Journal:  Int J Biol Markers       Date:  2000 Jan-Mar       Impact factor: 3.248

9.  Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver mestastasis vascularity and volume.

Authors:  M M Davies; S K Jonas; S Kaur; T G Allen-Mersh
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

Review 10.  Dendritic cells: immunological sentinels with a central role in health and disease.

Authors:  L H Stockwin; D McGonagle; I G Martin; G E Blair
Journal:  Immunol Cell Biol       Date:  2000-04       Impact factor: 5.126

View more
  17 in total

1.  Quantification of blood dendritic cells in colorectal cancer patients during the course of disease.

Authors:  Giulia Orsini; Annalisa Legitimo; Alessandra Failli; Paola Ferrari; Andrea Nicolini; Roberto Spisni; Paolo Miccoli; Rita Consolini
Journal:  Pathol Oncol Res       Date:  2013-09-11       Impact factor: 3.201

Review 2.  Role of prostanoids in gastrointestinal cancer.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  J Clin Invest       Date:  2018-05-07       Impact factor: 14.808

3.  Inhibition of IL-10 and TGF-β receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells.

Authors:  Chutamas Thepmalee; Aussara Panya; Mutita Junking; Thaweesak Chieochansin; Pa-Thai Yenchitsomanus
Journal:  Hum Vaccin Immunother       Date:  2018-02-21       Impact factor: 3.452

4.  Low expression of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in non-Hodgkin lymphoma and a significant correlation with β2-microglobulin.

Authors:  Dongbing Ding; Wenbin Chen; Changfu Zhang; Zhe Chen; Yanmei Jiang; Ziyi Yang; Xudong Jiang; Yunfei Zuo; Shuangyi Ren
Journal:  Med Oncol       Date:  2014-09-03       Impact factor: 3.064

Review 5.  OX40 as a novel target for the reversal of immune escape in colorectal cancer.

Authors:  Lin-Hai Yan; Xiao-Liang Liu; Si-Si Mo; Di Zhang; Xian-Wei Mo; Wei-Zhong Tang
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

6.  Use of antigen-primed dendritic cells for inducing antitumor immune responses in vitro in patients with non-small cell lung cancer.

Authors:  Irina Obleukhova; Nataliya Kiryishina; Svetlana Falaleeva; Julia Lopatnikova; Vasiliy Kurilin; Vadim Kozlov; Aleksander Vitsin; Andrey Cherkasov; Ekaterina Kulikova; Sergey Sennikov
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

7.  Alterations of dendritic cell subsets in the peripheral circulation of patients with cervical carcinoma.

Authors:  Feng Ye; Yan Yu; Yuting Hu; Weiguo Lu; Xing Xie
Journal:  J Exp Clin Cancer Res       Date:  2010-06-18

8.  Suppression of TGF-β and IL-10 receptors on self-differentiated dendritic cells by short-hairpin RNAs enhanced activation of effector T-cells against cholangiocarcinoma cells.

Authors:  Chutamas Thepmalee; Aussara Panya; Jatuporn Sujjitjoon; Nunghathai Sawasdee; Naravat Poungvarin; Mutita Junking; Pa-Thai Yenchitsomanus
Journal:  Hum Vaccin Immunother       Date:  2020-01-24       Impact factor: 3.452

Review 9.  An inflammatory mediator, prostaglandin E2, in colorectal cancer.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  Cancer J       Date:  2013 Nov-Dec       Impact factor: 3.360

10.  Augmentation of antitumor immunity by fusions of ethanol-treated tumor cells and dendritic cells stimulated via dual TLRs through TGF-β1 blockade and IL-12p70 production.

Authors:  Shigeo Koido; Sadamu Homma; Masato Okamoto; Yoshihisa Namiki; Kazuki Takakura; Akitaka Takahara; Shunichi Odahara; Shintaro Tsukinaga; Toyokazu Yukawa; Jimi Mitobe; Hiroshi Matsudaira; Keisuke Nagatsuma; Mikio Kajihara; Kan Uchiyama; Seiji Arihiro; Hiroo Imazu; Hiroshi Arakawa; Shin Kan; Kazumi Hayashi; Hideo Komita; Yuko Kamata; Masaki Ito; Eiichi Hara; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.